Overview In this role you lead the design and execution of in vivo anti-tumor efficacy and PK/PD studies to evaluate cancer drug candidates in CDX, PDX, and syngeneic models. You work within the Oncology Pharmacology team in Cambridge to develop novel in vivo assays and generate translational data that informs clinical development. You will mentor associates, collaborate across functions, and ensure rigorous data and animal protocol compliance. The opportunity centers on advancing early-stage oncology therapies in a highly matrixed environment, with impact on patient outcomes and translational research.
Compensation / Benefits- comprehensive benefits package
- 401(k) with company contribution and match
- health, life and disability coverage
- performance-based cash incentive
- eligibility for annual equity awards
- generous time off including vacation and holidays
Responsibilities- Design pre-clinical in vivo studies to test hypotheses and establish proof-of-concept
- Develop in vivo CDX, PDX, and syngeneic models to evaluate anti-tumor activity and PK/PD relationships
- Manage associate-level scientists
- Collaborate with cross-functional project teams
- Critically analyze and present results within a multidisciplinary team
- Ensure adherence to animal protocols and documentation of methods and data in electronic notebooks
Key requirements- PhD with 5-8 years of research experience in pharma/biotech
- Deep knowledge of antibody drug conjugates
- Extensive experience with CDX/PDX xenograft and/or syngeneic models
- Expertise in cell culture, PCR, ELISA, western blot, and flow cytometry
- Strong analytical, written and verbal communication, and organizational skills; proficient with PowerPoint and data analysis tools (Prism, Excel)
- high motivation
- inquisitiveness
- creativity
- antibody drug conjugates
- CDX/PDX/syngeneic in vivo models
- cell culture
